HBO and The Ringer's Bill Simmons hosts the most downloaded sports podcast of all time, with a rotating crew of celebrities, athletes, and media staples, as well as mainstays like Cousin Sal, Joe House, and a slew of other friends and family members who always happen to be suspiciously available.
…
continue reading
MP3•Episode home
Manage episode 519565630 series 3684506
Content provided by Ran Chen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ran Chen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this episode of MedTech Global Insights, we explore the booming field of Digital Therapeutics (DTx). We uncover what sets these evidence-based software platforms apart from simple wellness apps and dive deep into the number one obstacle holding them back from global adoption: the complex and fragmented regulatory landscape. We discuss the unique challenges of gaining market access in key regions like the United States (FDA), the European Union (MDR), and Asia (PMDA, MFDS). We break down why a one-size-fits-all approach to regulatory submissions is destined to fail and how a strategic, technology-driven process is essential for success. Consider a startup with a proven DTx for treating insomnia. They want to launch in Germany and Japan, but are immediately stuck. How do they navigate the EU's complex MDR requirements, appoint a local representative, and secure a CE mark while simultaneously preparing a completely different, translated submission dossier for Japan's PMDA? Without a unified strategy, they face overwhelming costs, delays, and the risk of fatal compliance errors. Key Takeaways: - How is a regulated Digital Therapeutic (DTx) platform fundamentally different from a consumer wellness app? - What are the critical first steps to determine your software's regulatory classification in the EU versus the US? - Why do different data privacy laws like GDPR and local Asian regulations pose a major challenge for DTx platforms? - What common, avoidable pitfalls lead to the rejection of SaMD submissions by regulatory authorities? - How can AI-powered tools dramatically accelerate the creation and adaptation of technical files for multiple markets? - What is the mandatory role of a Local Representative, and why is it so critical for post-market surveillance? - How can a "single process, multiple markets" strategy help a startup access over 30 countries efficiently? - What are the unique challenges of securing reimbursement for DTx products in different healthcare systems? To learn more about building your global MedTech strategy, contact us at [email protected] or visit https://pureglobal.com/.
…
continue reading
105 episodes